trending Market Intelligence /marketintelligence/en/news-insights/trending/q6rIpUvt7n8RZF4yGp3EmA2 content esgSubNav
In This List

Syndax to collaborate with National Cancer Institute on cancer treatments

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Syndax to collaborate with National Cancer Institute on cancer treatments

Syndax Pharmaceuticals Inc. entered an agreement with the U.S. National Cancer Institute to advance its Entinostat and SNDX-6352 cancer treatments.

The cooperative research and development agreement provides Syndax with the required facilities to conduct preclinical and clinical research of the treatments.

The studies will be led by the National Cancer Institute's chief of the Laboratory of Tumor Immunology and Biology, Jeffrey Schlom, and chief of the Genitourinary Malignancies Branch, James Gulley.

They will evaluate both Entinostat and SNDX-6352 as separate treatments and as a combined therapy for cancer. The drugs will also be evaluated in combination with other therapeutic regimens.